Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth USD 13 billion with US – based Biohaven Pharmaceutical (NYSE: BHVN) and South Korean biotech Aimed Bio Inc. The agreements coincide with the global launch of GeneQuantum’s IDiscovery, an intelligent automated development system for bioconjugated drugs. This marks a significant step forward for GeneQuantum in expanding its global footprint and leveraging its innovative ADC technology.
Global Development and Commercialization Rights
The alliances grant Biohaven and AimedBio global development and commercialization rights to GeneQuantum’s antibody drug conjugate (GQ1011). Under the terms of the agreements, GeneQuantum will empower Biohaven and AimedBio with innovative ADCs targeting a total of 21 targets. This collaboration aims to accelerate the development and commercialization of next – generation ADCs, leveraging GeneQuantum’s core conjugation technology and the partners’ expertise in oncology and drug development.
Strategic Alliances and Previous Collaborations
GeneQuantum previously partnered with AimedBio to develop an FGFR3 – targeted ADC product. According to one of the two deals struck this time, Biohaven will now hold the global development and commercialization rights for this product. The second agreement empowers Biohaven and its partner Merus to develop innovative ADCs targeting 18 specific targets using GeneQuantum’s core conjugation technology. This strategic move underscores GeneQuantum’s commitment to advancing ADCs through collaborative efforts with leading biotech companies.
IDiscovery Platform Launch
The global launch of GeneQuantum’s IDiscovery platform further highlights the company’s focus on innovation and automation in drug development. IDiscovery is designed to streamline the development process of bioconjugated drugs, offering a more efficient and intelligent approach to creating next – generation ADCs. This platform is expected to play a crucial role in accelerating the discovery and development of new ADCs, ultimately improving patient outcomes in oncology and other therapeutic areas.-Fineline Info & Tech
Leave a Reply